GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Sernova Corp (FRA:PSH) » Definitions » EV-to-FCF

Sernova (FRA:PSH) EV-to-FCF : -3.31 (As of May. 12, 2024)


View and export this data going back to 2014. Start your Free Trial

What is Sernova EV-to-FCF?

EV-to-FCF is calculated as enterprise value divided by its free cash flow. As of today, Sernova's Enterprise Value is €66.02 Mil. Sernova's Free Cash Flow for the trailing twelve months (TTM) ended in Jan. 2024 was €-19.94 Mil. Therefore, Sernova's EV-to-FCF for today is -3.31.

The historical rank and industry rank for Sernova's EV-to-FCF or its related term are showing as below:

FRA:PSH' s EV-to-FCF Range Over the Past 10 Years
Min: -111.06   Med: 0   Max: 0
Current: -3.34

FRA:PSH's EV-to-FCF is ranked worse than
100% of 390 companies
in the Biotechnology industry
Industry Median: 6.365 vs FRA:PSH: -3.34

EV-to-FCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio to determine the fair market value of a company.

As of today (2024-05-12), Sernova's stock price is €0.241. Sernova's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Jan. 2024 was €-0.090. Therefore, Sernova's PE Ratio for today is At Loss.


Sernova EV-to-FCF Historical Data

The historical data trend for Sernova's EV-to-FCF can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Sernova EV-to-FCF Chart

Sernova Annual Data
Trend Oct14 Oct15 Oct16 Oct17 Oct18 Oct19 Oct20 Oct21 Oct22 Oct23
EV-to-FCF
Get a 7-Day Free Trial Premium Member Only Premium Member Only -8.39 -10.50 -43.57 -13.10 -6.93

Sernova Quarterly Data
Apr19 Jul19 Oct19 Jan20 Apr20 Jul20 Oct20 Jan21 Apr21 Jul21 Oct21 Jan22 Apr22 Jul22 Oct22 Jan23 Apr23 Jul23 Oct23 Jan24
EV-to-FCF Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -14.06 -10.08 -10.28 -6.93 -6.05

Competitive Comparison of Sernova's EV-to-FCF

For the Biotechnology subindustry, Sernova's EV-to-FCF, along with its competitors' market caps and EV-to-FCF data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Sernova's EV-to-FCF Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Sernova's EV-to-FCF distribution charts can be found below:

* The bar in red indicates where Sernova's EV-to-FCF falls into.



Sernova EV-to-FCF Calculation

Sernova's EV-to-FCF for today is calculated as:

EV-to-FCF=Enterprise Value (Today)/Free Cash Flow (TTM)
=66.016/-19.941
=-3.31

Sernova's current Enterprise Value is €66.02 Mil.
Sernova's Free Cash Flow for the trailing twelve months (TTM) ended in Jan. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was €-19.94 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Sernova  (FRA:PSH) EV-to-FCF Explanation

EV-to-FCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio to determine the fair market value of a company.

Sernova's PE Ratio for today is calculated as:

PE Ratio=Share Price (Today)/Earnings per Share (Diluted) (TTM)
=0.241/-0.090
=At Loss

Sernova's share price for today is €0.241.
Sernova's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Jan. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was €-0.090.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Enterprise Value is used because it is a more complete measure in reflecting how much an investor pays when buying a company. Free Cash Flow is an important financial metric because it represents the actual amount of cash at a company's disposal. Companies with a low EV-to-FCF ratio, combined with a strong balance sheet are generally considered as undervalued.


Sernova EV-to-FCF Related Terms

Thank you for viewing the detailed overview of Sernova's EV-to-FCF provided by GuruFocus.com. Please click on the following links to see related term pages.


Sernova (FRA:PSH) Business Description

Traded in Other Exchanges
Address
700 Collip Circle, The Stiller Centre, Suite 114, London, ON, CAN, N6G 4X8
Sernova Corp is a clinical-stage company developing products for the treatment of chronic debilitating diseases. The company is engaged in the research and development of its proprietary Cell Pouch and associated technologies including immune-protected therapeutic cells. The Cell Pouch is a scalable, implantable medical device designed to create a vascularized tissue environment for the transplantation and engraftment of therapeutic cells, which then release proteins and or hormones for the long-term treatment of multiple serious, chronic diseases such as diabetes, hemophilia, and thyroid disease.

Sernova (FRA:PSH) Headlines